Oncopeptides presents new scientific data at European Myeloma Network Meeting
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company presents new scientific data on melflufen at the European Myeloma Network meeting in Amsterdam on April 20. The data includes one abstract on health-related quality of life outcomes from the phase 3 OCEAN study, and one abstract from the phase 3 LIGHTHOUSE study.
“Relapsed refractory multiple myeloma (RRMM) is associated with severe symptoms including pain, fatigue, physical and emotional functioning, and most patients experience impaired health-related quality of life (HRQoL),” says Fredrik Schjesvold, MD, Head of Oslo Myeloma Center. “The results from OCEAN are important since HRQoL was maintained throughout the treatment with melflufen plus dexamethasone and was similar to the outcome from the treatment with pomalidomide plus dexamethasone.”
“Data from the LIGHTHOUSE study is very encouraging and clearly indicates that the combination of melflufen plus daratumumab has a clinical benefit in patients with RRMM,” says María-Victoria Mateos, MD, PhD, from Salamanca’s University Hospital Haematology Department, and Lead Investigator of the LIGHTHOUSE study. “Multiple myeloma is still an incurable disease for most patients, and we welcome additional evidence on how to combine treatment options with different mode of actions in clinical practice.”
Below is a brief description of the abstracts that have been accepted by the European Myeloma Network. The abstracts are available online through the following link, click here.
|Scientific abstracts||First author||Publication|
|Patient-reported outcomes (pro) in relapsed/refractory multiple myeloma (RRMM) treated with melflufen and dexamethasone (dex) or pomalidomide (pom) and dex: analyses from the phase 3 ocean study.||Fredrik Schjesvold, MD, Head of Oslo Myeloma Center, Oslo University Hospital||Poster P 38|
|Lighthouse (op-108): melflufen plus daratumumab (dara) and dexamethasone (dex) versus dara in relapsed/refractory multiple myeloma (RRMM) refractory to an immunomodulatory drug (imid) and a proteasome inhibitor (pi) or had received ≥3 prior lines of therapy including an imid and a pi.||María-Victoria Mateos, MD, PhD, from Salamanca’s University Hospital Haematology Department,||Poster P 34|